+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
A

Actively Recruiting

Researchers are evaluating ibuzatrelvir to determine its effectiveness and safety in treating adults and adolescents aged 12 and older who have COVID-19 but are not hospitalized. The study focuses on individuals at high risk of progressing to severe illness. Participants will be randomly assigned to receive either ibuzatrelvir or a placebo, alongside standard care as available locally, with the study lasting approximately six months. Participants will receive either ibuzatrelvir tablets or placebo tablets orally every 12 hours for five days. This is a randomized, double-blind, phase 3 study comparing the investigational drug to placebo. The study allows co-administration of locally available standard treatments. The treatment period is followed by monitoring to assess outcomes related to COVID-19 progression and symptom resolution. During the study, participants will be observed for emergency department visits, hospitalizations, mortality, symptom resolution, and viral load changes over 28 days and up to 24 weeks. Researchers will collect data on medical events, including cardiovascular, renal, and pulmonary complications, as well as Long COVID symptoms. Safety is monitored through adverse event tracking. Overall participation lasts about six months with multiple assessments during this time.

Age: 12Years +All GendersPhase 3
256 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
E

Actively Recruiting

Researchers are evaluating the safety and efficacy of ibuzatrelvir alone and in combination with remdesivir compared to remdesivir alone in treating symptomatic COVID-19 among severely immunocompromised adults. This Phase 3, randomized, double-blind study focuses on participants who are non-hospitalized or have mild-to-moderate COVID-19 at baseline. The trial aims to better understand treatment options for this vulnerable patient group who may face prolonged infections and severe illness progression. Participants are assigned to one of three groups ibuzatrelvir taken orally twice daily plus intravenous remdesivir, ibuzatrelvir plus intravenous placebo, or oral placebo plus intravenous remdesivir. The study uses matching placebos to maintain blinding. Treatment durations and specific dosing schedules are carefully monitored to compare the combination and monotherapy effects over the study period. During approximately 10 study visits over 24 weeks, participants will attend clinic visits for blood tests, nasal swabs collected both in-clinic and at home, and complete questionnaires. Researchers will assess outcomes such as symptom alleviation, viral RNA levels, rates of infection recurrence, hospital visits, and safety events. This comprehensive monitoring helps evaluate the impact of the treatments on COVID-19 symptoms and viral clearance in immunocompromised adults.

Age: 18Years +All GendersPhase 3
159 locations
E

Actively Recruiting

Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.

Age: 18Years +All GendersPhase 3
279 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations

1-10 of 14

1